Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496399 | 0.88 | HRH4 (0.53) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396152 | 0.88 | HRH4 (0.53) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396240 | 0.88 | HRH4 (0.53) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396162 | 0.85 | HRH4 (0.50) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396045 | 0.85 | HRH4 (0.50) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396103 | 0.84 | HRH4 (0.49) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396122 | 0.84 | GRM5 (0.55) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22633765 | 0.84 | KMT2A (0.52) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22396085 | 0.84 | HRH4 (0.54) | MAPK14POLBSMN1; SMN2HRH4HRH3 | |
| SCHEMBL22395909 | 0.84 | POLB (0.59) | MAPK14POLBSMN1; SMN2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-08 | — | — | US | disclosed |
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
| EP-3704127-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | MAPK14 1907/4885POLB 895/4885SMN1; SMN2 4881/4885 |
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, IDO2 | MAPK14 1873/4885POLB 655/4885SMN1; SMN2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.